Cargando…

Correction to: CGRP induces migraine-like symptoms in mice during both the active and inactive phases

Detalles Bibliográficos
Autores principales:	Wattiez, Anne-Sophie, Gaul, Olivia J., Kuburas, Adisa, Zorrilla, Erik, Waite, Jayme S., Mason, Bianca N., Castonguay, William C., Wang, Mengya, Robertson, Bennett R., Russo, Andrew F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491374/ https://www.ncbi.nlm.nih.gov/pubmed/34610787 http://dx.doi.org/10.1186/s10194-021-01332-5

Ejemplares similares

CGRP induces migraine-like symptoms in mice during both the active and inactive phases
por: Wattiez, Anne-Sophie, et al.
Publicado: (2021)

Shared and independent roles of CGRP and PACAP in migraine pathophysiology
por: Kuburas, Adisa, et al.
Publicado: (2023)

A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine
por: von Mentzer, Bengt, et al.
Publicado: (2020)

CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

Dural Immune Cells, CGRP, and Migraine
por: Balcziak, Louis K., et al.
Publicado: (2022)

CGRP Administration Into the Cerebellum Evokes Light Aversion, Tactile Hypersensitivity, and Nociceptive Squint in Mice
por: Wang, Mengya, et al.
Publicado: (2022)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Serotonin and CGRP in Migraine
por: Aggarwal, Milan, et al.
Publicado: (2012)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

Gender aspects of CGRP in migraine
por: Labastida-Ramírez, Alejandro, et al.
Publicado: (2017)

CGRP and the Trigeminal System in Migraine
por: Iyengar, Smriti, et al.
Publicado: (2019)

Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021)

CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far?
por: Kamm, Katharina
Publicado: (2022)

CGRP and migraine: neurogenic inflammation revisited
por: Geppetti, P., et al.
Publicado: (2005)

CGRP receptors and TRP channels in migraine
por: Geppetti, Pierangelo, et al.
Publicado: (2015)

CGRP as a Migraine Inducing Substance
por: Olesen, J., et al.
Publicado: (2001)

Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
por: Scuteri, Damiana, et al.
Publicado: (2021)

Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor
por: Blumenfeld, Andrew, et al.
Publicado: (2021)

Stimulation of CGRP-expressing neurons in the medial cerebellar nucleus induces light and touch sensitivity in mice
por: Wang, Mengya, et al.
Publicado: (2022)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Migraine therapeutics differentially modulate the CGRP pathway
por: Bhakta, Minoti, et al.
Publicado: (2021)

Future targets for migraine treatment beyond CGRP
por: Al-Hassany, Linda, et al.
Publicado: (2023)

Effect of Xiongmatang Extract on Behavioral and TRPV1-CGRP/CGRP-R Pathway in Rats With Migraine
por: Liu, Dingding, et al.
Publicado: (2022)

New Anti-CGRP Medications in the Treatment of Vestibular Migraine
por: Hoskin, Justin L., et al.
Publicado: (2022)

The Responses to CGRP in the Territory of the Posterior Cerebral Artery in Migraine
por: Visočnik, Darja, et al.
Publicado: (2022)

Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine
por: Fila, Michal, et al.
Publicado: (2023)

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
por: Favoni, Valentina, et al.
Publicado: (2019)

Is prednisone still a reasonable option in the treatment of withdrawal headache in patients with chronic migraine and medication overuse headache in the age of CGRP antibodies? A narrative review
por: Kaltseis, Katharina, et al.
Publicado: (2022)

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy
por: Holland, Philip R., et al.
Publicado: (2018)

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
por: Tso, Amy R., et al.
Publicado: (2017)

Blocking CGRP in migraine patients – a review of pros and cons
por: Deen, Marie, et al.
Publicado: (2017)

The potential danger of blocking CGRP for treating migraine in CADASIL patients
por: de Boer, Irene, et al.
Publicado: (2020)

CGRP in Childhood and Adolescence Migraine: (Patho)physiological and Clinical Aspects
por: Evers, Stefan
Publicado: (2022)

The Vasodilatory Response to CGRP of the Anterior and Posterior Cerebral Circulation in Migraine
por: Visočnik, Darja, et al.
Publicado: (2022)

Serum CGRP in migraine patients using erenumab as preventive treatment
por: de Vries Lentsch, Simone, et al.
Publicado: (2022)

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine
por: Chowdhury, Selia, et al.
Publicado: (2023)

Plasma calcitonin gene‐related peptide (CGRP) in migraine and endometriosis during the menstrual cycle
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
por: Straube, Andreas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_59fof7kaj65sf3r94sndfebs3b